During the last session, P3 Health Partners Inc (NASDAQ:PIII)’s traded shares were 0.7 million, with the beta value of the company hitting 0.91. At the end of the trading day, the stock’s price was $0.17, reflecting an intraday loss of -4.59% or -$0.01. The 52-week high for the PIII share is $1.12, that puts it down -558.82 from that peak though still a striking 11.76% gain since the share price plummeted to a 52-week low of $0.15. The company’s market capitalization is $61.94M, and the average intraday trading volume over the past 10 days was 1.08 million shares, and the average trade volume was 2.50 million shares over the past three months.
P3 Health Partners Inc (PIII) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.80. PIII has a Sell rating from 0 analyst(s) out of 2 analysts who have looked at this stock. 1 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 1 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be 0.
P3 Health Partners Inc (NASDAQ:PIII) trade information
P3 Health Partners Inc (PIII) registered a -4.59% downside in the last session and has traded in the green over the past 5 sessions. The stock plummet -4.59% in intraday trading to $0.17, hitting a weekly high. The stock’s 5-day price performance is 0.29%, and it has moved by -9.69% in 30 days. Based on these gigs, the overall price performance for the year is -81.29%. The short interest in P3 Health Partners Inc (NASDAQ:PIII) is 2.34 million shares and it means that shorts have 3.26 day(s) to cover.
P3 Health Partners Inc (PIII) estimates and forecasts
In the rating firms’ projections, revenue will decrease -6.52% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 363.45M as predicted by 3 analyst(s). Meanwhile, a consensus of 3 analyst(s) estimates revenue growth to 349.77M by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 388.49M and 379.16M respectively. In this case, analysts expect current quarter sales to shrink by -6.44% and then drop by -7.75% in the coming quarter.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -4.17%. While earnings are projected to return 51.28% in 2025, the next five years will return 41.31% per annum.
PIII Dividends
P3 Health Partners Inc is due to release its next quarterly earnings on 2025-Mar-26. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
P3 Health Partners Inc (NASDAQ:PIII)’s Major holders
P3 Health Partners Inc insiders own 62.08% of total outstanding shares while institutional holders control 13.27%, with the float percentage being 35.00%. ALYESKA INVESTMENT GROUP, L.P. is the largest shareholder of the company, while 44.0 institutions own stock in it. As of 2024-06-30, the company held over 15.95 million shares (or 11.6756% of all shares), a total value of $7.18 million in shares.
The next largest institutional holding, with 7.9 million shares, is of ARMISTICE CAPITAL, LLC’s that is approximately 5.7833% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $3.56 million.
Also, the Mutual Funds coming in first place with the largest holdings of P3 Health Partners Inc (PIII) shares are VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and Fidelity Concord Street Trust-Fidelity Extended Market Index Fund . Data provided on Dec 31, 2024 indicates that VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund owns about 1.45 shares. This amounts to just over 0.89 percent of the company’s overall shares, with a $0.25 million market value. The same data shows that the other fund manager holds slightly less at 462.69, or about 0.28% of the stock, which is worth about $79813.0.
